Table 1.
Baseline characteristics of our study.
| Variables | IFX monotherapy group (N = 22) | IFX-AZA sequential therapy group (N = 57) | All (N = 79) | P value |
|---|---|---|---|---|
| Male sex, n (%) | 16 (72.7) | 38 (66.7) | 54 (68.4) | 0.604 |
| Duration of symptoms (week) | 27.1 ± 13.5 | 28.3 ± 14.1 | 28.0 ± 13.9 | 0.733 |
| Age of onset (yr) | 26.9 ± 9.8 | 24.2 ± 8.2 | 25.0 ± 8.7 | 0.217 |
| Location of lesions, n (%) | 0.829 | |||
| Ileum | 6 (27.3) | 20 (35.1) | 26 (32.9) | |
| Colon | 3 (13.6) | 6 (10.5) | 9 (11.4) | |
| Ileocolon | 12 (54.5) | 30 (52.6) | 42 (53.2) | |
| Upper GI tract | 1 (4.5) | 1 (1.8) | 2 (2.5) | |
| Behavior of disease, n (%) | 0.252 | |||
| Nonstenosis, nonfistula | 14 (63.6) | 46 (80.7) | 60 (75.9) | |
| Stenosis | 4 (18.2) | 7 (12.3) | 11 (13.9) | |
| Fistula | 4 (18.2) | 4 (7.0) | 8 (10.1) | |
| Perianal disease, n (%) | 9 (40.9) | 20 (35.1) | 29 (36.7) | 0.630 |
| CDAI | 344.9 ± 51.0 | 331.8 ± 61.6 | 334.9 ± 58.7 | 0.457 |
| CDEIS | 14.2 ± 3.8 | 14.1 ± 3.9 | 14.1 ± 3.9 | 0.964 |
| Deep remission at week 30 | 13 (59.1) | 31 (54.4) | 44 (55.7) | 0.706 |
| Complete endoscopic remission at week 30 | 13 (59.1) | 31 (54.4) | 44 (55.7) | 0.706 |
| Endoscopic remission at week 30 | 19 (86.4) | 42 (73.7) | 61 (77.2) | 0.365 |
| Endoscopic improvement at week 30 | 21 (95.5) | 54 (94.7) | 75 (94.9) | 0.999 |